Home

PARAG SAXENA

CIK 1015823 · Chief Executive Officer · last filed 2025-12-19

PARAG SAXENA is a Chief Executive Officer who has filed 9 SEC Form 4 insider transactions across 4 companies since 2018. The most recent filing, for RVPH, was dated Dec 19, 2025. Across all open-market trades the lifetime net is +$3.4M, making them a net buyer over the disclosed history. 3 SEC filings were submitted jointly with VEDANTA ASSOCIATES, L.P.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

4

Total Filings

9

Lifetime Open-Market Net

$3.43M

Filer Profile

Reported Address
250 WEST 55TH STREET, SUITE 13D
NEW YORK, NY 10019
State of Incorporation
DE
Related Filers
VEDANTA ASSOCIATES, L.P. — 3 joint filings, latest 2023-11-22
Rahul Nayar — 2 joint filings, latest 2020-12-28
Tenzing LLC — 2 joint filings, latest 2020-12-28
Vedanta Associates-R, LP — 2 joint filings, latest 2022-09-12
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) Delisted Director — $0.71 — $0 1 2025-12-19
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW) Delisted Director — $0.00 — $0 5 2024-12-12
Eucrates Biomedical Acquisition Corp. (EUCRU) Delisted Chief Executive Officer 2,619,906 $10.02 $26.25M $0 1 2020-11-27
REVIVA PHARMACEUTICALS HOLDINGS, INC. (TZACU) Delisted Chairman of the Board 1,924,250 — — $3.43M 2 2018-09-04

Recent Filings

9 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-12-19 REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) Delisted Grant (A) — $0 EDGAR
2024-12-12 REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW) Delisted Grant (A) — $0 EDGAR
2023-11-14 REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW) Delisted Grant (A) — $0 EDGAR
2022-11-14 REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW) Delisted Grant (A) — $0 EDGAR
2021-12-10 REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW) Delisted Grant (A) — $0 EDGAR
2021-06-16 REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW) Delisted Grant (A) — $0 EDGAR
2020-11-27 Eucrates Biomedical Acquisition Corp. (EUCRU) Delisted Other (J) −255,094 $0 EDGAR
2018-09-04 REVIVA PHARMACEUTICALS HOLDINGS, INC. (TZACU) Delisted Buy (P) +33,000 $330.0K EDGAR
2018-08-24 REVIVA PHARMACEUTICALS HOLDINGS, INC. (TZACU) Delisted Buy (P) +310,000 $3.10M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.